ClinicalTrials.Veeva

Menu

Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety (SORINT)

Bayer logo

Bayer

Status

Completed

Conditions

Carcinoma, Hepatocellular

Treatments

Drug: Sorafenib (Nexavar, BAY43-9006)

Study type

Observational

Funder types

Industry

Identifiers

Details and patient eligibility

About

The study aims to investigate patient characteristics of intermediate stage hepatocellular carcinoma patients treated with Nexavar and their distribution to different treatment groups as well as determining efficacy and safety parameters.

Enrollment

19 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with a diagnosis of unresectable intermediate stage hepatocellular carcinoma (BCLC-B) for whom the decision has been taken by the investigator to prescribe Nexavar (the BCLC intermediate stage (BCLC-B) consists of Child-Pugh A and B patients with large/multifocal HCC who do not have cancer related symptoms, macrovascular invasion or extrahepatic spread).

Exclusion criteria

  • Prior targeted therapy for hepatocellular carcinoma.

Trial design

19 participants in 1 patient group

Group 1
Treatment:
Drug: Sorafenib (Nexavar, BAY43-9006)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems